{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T10:04:57Z","timestamp":1779185097489,"version":"3.51.4"},"posted":{"date-parts":[[2021,3,1]]},"group-title":"Immunology","reference-count":73,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2021,3,1]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n                <jats:p>The emergence of SARS-CoV-2 variants highlighted the need to better understand adaptive immune responses to this virus. It is important to address whether also CD4+ and CD8+ T cell responses are affected, because of the role they play in disease resolution and modulation of COVID-19 disease severity. Here we performed a comprehensive analysis of SARS-CoV-2-specific CD4+ and CD8+ T cell responses from COVID-19 convalescent subjects recognizing the ancestral strain, compared to variant lineages B.1.1.7, B.1.351, P.1, and CAL.20C as well as recipients of the Moderna (mRNA-1273) or Pfizer\/BioNTech (BNT162b2) COVID-19 vaccines. Similarly, we demonstrate that the sequences of the vast majority of SARS-CoV-2 T cell epitopes are not affected by the mutations found in the variants analyzed. Overall, the results demonstrate that CD4+ and CD8+ T cell responses in convalescent COVID-19 subjects or COVID-19 mRNA vaccinees are not substantially affected by mutations found in the SARS-CoV-2 variants.<\/jats:p>","DOI":"10.1101\/2021.02.27.433180","type":"posted-content","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T13:35:32Z","timestamp":1614692132000},"source":"Crossref","is-referenced-by-count":106,"title":["Negligible impact of SARS-CoV-2 variants on CD4\n                  <sup>+<\/sup>\n                  and CD8\n                  <sup>+<\/sup>\n                  T cell reactivity in COVID-19 exposed donors and vaccinees"],"prefix":"10.64898","author":[{"given":"Alison","family":"Tarke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Sidney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Methot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1180-275X","authenticated-orcid":false,"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Dan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Rubiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9785-5272","authenticated-orcid":false,"given":"Ricardo","family":"da Silva Antunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April","family":"Frazier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen A.","family":"Rawlings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davey M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bjoern","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H.","family":"Scheuermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Weiskopf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6484-6262","authenticated-orcid":false,"given":"Shane","family":"Crotty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2209-5966","authenticated-orcid":false,"given":"Alba","family":"Grifoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Sette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2021030306150624000_2021.02.27.433180v1.1","doi-asserted-by":"crossref","unstructured":"Amit, S. , Regev-Yochay, G. , Afek, A. , Kreiss, Y. , and Leshem, E. (2021). Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet.","DOI":"10.1016\/S0140-6736(21)00448-7"},{"key":"2021030306150624000_2021.02.27.433180v1.2","unstructured":"Andreano, E. , Piccini, G. , Licastro, D. , Casalino, L. , Johnson, N.V. , Paciello, I. , Monego, S.D. , Pantano, E. , Manganaro, N. , Manenti, A. , et al. (2020). SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv, 2020.2012.2028.424451."},{"key":"2021030306150624000_2021.02.27.433180v1.3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad0522"},{"key":"2021030306150624000_2021.02.27.433180v1.4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"2021030306150624000_2021.02.27.433180v1.5","doi-asserted-by":"crossref","unstructured":"Braun, J. , Loyal, L. , Frentsch, M. , Wendisch, D. , Georg, P. , Kurth, F. , Hippenstiel, S. , Dingeldey, M. , Kruse, B. , Fauchere, F. , et al. (2020). SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature.","DOI":"10.1038\/s41586-020-2598-9"},{"key":"2021030306150624000_2021.02.27.433180v1.6","doi-asserted-by":"crossref","unstructured":"Breton, G. , Mendoza, P. , Hagglof, T. , Oliveira, T.Y. , Schaefer-Babajew, D. , Gaebler, C. , Turroja, M. , Hurley, A. , Caskey, M. , and Nussenzweig, M.C. (2021). Persistent cellular immunity to SARS-CoV-2 infection. J Exp Med 218.","DOI":"10.1084\/jem.20202515"},{"key":"2021030306150624000_2021.02.27.433180v1.7","unstructured":"Cele, S. , Gazy, I. , Jackson, L. , Hwa, S.-H. , Tegally, H. , Lustig, G. , Giandhari, J. , Pillay, S. , Wilkinson, E. , Naidoo, Y. , et al. (2021). Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma. medRxiv, 2021.2001.2026.21250224."},{"key":"2021030306150624000_2021.02.27.433180v1.8","doi-asserted-by":"crossref","unstructured":"da Silva Antunes, R. , Pallikkuth, S. , Williams, E. , Yu, E.D. , Mateus, J. , Quiambao, L. , Wang, E. , Rawlings, S.A. , Stadlbauer, D. , Jiang, K. , et al. (2021). Differential T cell reactivity to seasonal coronaviruses and SARS-CoV-2 in community and health care workers. medRxiv.","DOI":"10.1101\/2021.01.12.21249683"},{"key":"2021030306150624000_2021.02.27.433180v1.9","doi-asserted-by":"crossref","unstructured":"Dan, J.M. , Mateus, J. , Kato, Y. , Hastie, K.M. , Yu, E.D. , Faliti, C.E. , Grifoni, A. , Ramirez, S.I. , Haupt, S. , Frazier, A. , et al. (2021). Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371.","DOI":"10.1126\/science.abf4063"},{"key":"2021030306150624000_2021.02.27.433180v1.10","unstructured":"Davies, N.G. , Barnard, R.C. , Jarvis, C.I. , Kucharski, A.J. , Munday, J. , Pearson, C.A.B. , Russell, T.W. , Tully, D.C. , Abbott, S. , Gimma, A. , et al. (2020). Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012\/01 in England. medRxiv, 2020.2012.2024.20248822."},{"key":"2021030306150624000_2021.02.27.433180v1.11","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz452"},{"key":"2021030306150624000_2021.02.27.433180v1.12","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/s41467-018-03665-3","article-title":"How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin","volume":"9","year":"2018","journal-title":"Nature communications"},{"key":"2021030306150624000_2021.02.27.433180v1.13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5498\/wjp.v10.i3.21","article-title":"Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia","volume":"10","year":"2020","journal-title":"World journal of psychiatry"},{"key":"2021030306150624000_2021.02.27.433180v1.14","doi-asserted-by":"crossref","unstructured":"Edara, V.V. , Floyd, K. , Lai, L. , Gardner, M. , Hudson, W. , Piantadosi, A. , Waggoner, J.J. , Babiker, A. , Ahmed, R. , Xie, X. , et al. (2021). Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant. medRxiv, 2021.2002.2002.21250799.","DOI":"10.1101\/2021.02.02.21250799"},{"key":"2021030306150624000_2021.02.27.433180v1.15","unstructured":"Emary, K. , Golubchik, T. , Aley, P. , Ariani, C. , Angus, B.J. , Bibi, S. , Blane, B. , Bonsall, D. , Cicconi, P. , Charlton, S. , et al. (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012\/01 (B.1.1.7) (SSRN)."},{"key":"2021030306150624000_2021.02.27.433180v1.16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1833816"},{"key":"2021030306150624000_2021.02.27.433180v1.17","unstructured":"FDA (2021a). Vaccines and Related Biological Products Advisory Committee February 26, 2021 Meeting Briefing Document Addendum- Sponsor"},{"key":"2021030306150624000_2021.02.27.433180v1.18","unstructured":"FDA (2021b). Vaccines and Related Biological Products Advisory Committee February 26, 2021 Meeting Briefing Document- Sponsor."},{"key":"2021030306150624000_2021.02.27.433180v1.19","doi-asserted-by":"crossref","unstructured":"Ferretti, A.P. , Kula, T. , Wang, Y. , Nguyen, D.M.V. , Weinheimer, A. , Dunlap, G.S. , Xu, Q. , Nabilsi, N. , Perullo, C.R. , Cristofaro, A.W. , et al. (2020). Unbiased Screens Show CD8(+) T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. Immunity.","DOI":"10.1016\/j.immuni.2020.10.006"},{"key":"2021030306150624000_2021.02.27.433180v1.20","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav5095"},{"key":"2021030306150624000_2021.02.27.433180v1.21","doi-asserted-by":"crossref","unstructured":"Greaney, A.J. , Loes, A.N. , Crawford, K.H.D. , Starr, T.N. , Malone, K.D. , Chu, H.Y. , and Bloom, J.D. (2021). Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell host & microbe.","DOI":"10.1016\/j.chom.2021.02.003"},{"key":"2021030306150624000_2021.02.27.433180v1.22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0911580106"},{"key":"2021030306150624000_2021.02.27.433180v1.23","doi-asserted-by":"crossref","unstructured":"Grifoni, A. , Voic, H. , Dhanda, S.K. , Kidd, C.K. , Brien, J.D. , Buus, S. , Stryhn, A. , Durbin, A.P. , Whitehead, S. , and Diehl, S.A. (2020a). T cell responses induced by attenuated flavivirus vaccination are specific and show limited cross-reactivity with other flavivirus species. Journal of virology 94.","DOI":"10.1128\/JVI.00089-20"},{"key":"2021030306150624000_2021.02.27.433180v1.24","doi-asserted-by":"crossref","unstructured":"Grifoni, A. , Weiskopf, D. , Ramirez, S.I. , Mateus, J. , Dan, J.M. , Moderbacher, C.R. , Rawlings, S.A. , Sutherland, A. , Premkumar, L. , Jadi, R.S. , et al. (2020b). Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell.","DOI":"10.1016\/j.cell.2020.05.015"},{"key":"2021030306150624000_2021.02.27.433180v1.25","unstructured":"Hall, V.J. , Foulkes, S. , Saei, A. , Andrews, N. , ,, Oguti, B. , Charlett, A. , Wellington, E. , Stowe, J. , Gillson, N. , Atti, A. , et al. (2021). Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study). http:\/\/dx.doi.org\/10.2139\/ssrn.3790399.Ssrn."},{"key":"2021030306150624000_2021.02.27.433180v1.26","doi-asserted-by":"publisher","DOI":"10.1126\/science.1178258"},{"key":"2021030306150624000_2021.02.27.433180v1.27","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine","volume":"383","year":"2020","journal-title":"N Engl J Med"},{"key":"2021030306150624000_2021.02.27.433180v1.28","doi-asserted-by":"crossref","unstructured":"Keller, M.D. , Harris, K.M. , Jensen-Wachspress, M.A. , Kankate, V. , Lang, H. , Lazarski, C.A. , Durkee-Shock, J.R. , Lee, P.H. , Chaudhry, K. , Webber, K. , et al. (2020). SARS-CoV-2 specific T-cells Are Rapidly Expanded for Therapeutic Use and Target Conserved Regions of Membrane Protein. Blood.","DOI":"10.1182\/blood.2020008488"},{"key":"2021030306150624000_2021.02.27.433180v1.29","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S2213-2600(21)00005-9","article-title":"New variant of SARS-CoV-2 in UK causes surge of COVID-19","volume":"9","year":"2021","journal-title":"The Lancet Respiratory medicine"},{"key":"2021030306150624000_2021.02.27.433180v1.30","doi-asserted-by":"crossref","unstructured":"Krammer, F. , Garcia-Sastre, A. , and Palese, P. (2018). Is It Possible to Develop a \u201cUniversal\u201d Influenza Virus Vaccine? Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine. Cold Spring Harbor perspectives in biology 10.","DOI":"10.1101\/cshperspect.a028845"},{"key":"2021030306150624000_2021.02.27.433180v1.31","unstructured":"Le Bert, N. , Tan, A.T. , Kunasegaran, K. , Tham, C.Y.L. , Hafezi, M. , Chia, A. , Chng, M.H.Y. , Lin, M. , Tan, N. , Linster, M. , et al. (2020). SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature."},{"key":"2021030306150624000_2021.02.27.433180v1.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00460-4"},{"key":"2021030306150624000_2021.02.27.433180v1.33","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd3871"},{"key":"2021030306150624000_2021.02.27.433180v1.34","unstructured":"Muik, A. , Wallisch, A.K. , Sanger, B. , Swanson, K.A. , Muhl, J. , Chen, W. , Cai, H. , Maurus, D. , Sarkar, R. , Tureci, O. , et al. (2021). Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science."},{"key":"2021030306150624000_2021.02.27.433180v1.35","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","article-title":"Animal models for COVID-19","volume":"586","year":"2020","journal-title":"Nature"},{"key":"2021030306150624000_2021.02.27.433180v1.36","doi-asserted-by":"crossref","unstructured":"Nelde, A. , Bilich, T. , Heitmann, J.S. , Maringer, Y. , Salih, H.R. , Roerden, M. , Lubke, M. , Bauer, J. , Rieth, J. , Wacker, M. , et al. (2020). SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol.","DOI":"10.1038\/s41590-020-00808-x"},{"key":"2021030306150624000_2021.02.27.433180v1.37","unstructured":"Novavax Inc. (2021). Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial."},{"key":"2021030306150624000_2021.02.27.433180v1.38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005456117"},{"key":"2021030306150624000_2021.02.27.433180v1.39","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","year":"2020","journal-title":"Nat Immunol"},{"key":"2021030306150624000_2021.02.27.433180v1.40","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr859"},{"key":"2021030306150624000_2021.02.27.433180v1.41","unstructured":"Rambaut, A. , Loman, N. , Pybus, O. , Barclay, W. , Barrett, J. , Carabelli, A. , Connor, T. , Peacock, T. , Robertson, D.L. , and E, V. (2020). Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. https:\/\/virologicalorg\/t\/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations\/563."},{"key":"2021030306150624000_2021.02.27.433180v1.42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186998"},{"key":"2021030306150624000_2021.02.27.433180v1.43","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2021030306150624000_2021.02.27.433180v1.44","unstructured":"Rydyznski Moderbacher, C. , Ramirez, S.I. , Dan, J.M. , Grifoni, A. , Hastie, K.M. , Weiskopf, D. , Belanger, S. , Abbott, R.K. , Kim, C. , Choi, J. , et al. (2020). Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell."},{"key":"2021030306150624000_2021.02.27.433180v1.45","unstructured":"Sadoff, J. , Le Gars, M. , Shukarev, G. , Heerwegh, D. , Truyers, C. , de Groot, A.M. , Stoop, J. , Tete, S. , Van Damme, W. , Leroux-Roels, I. , et al. (2021). Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med."},{"key":"2021030306150624000_2021.02.27.433180v1.46","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","year":"2021","journal-title":"Cell"},{"key":"2021030306150624000_2021.02.27.433180v1.47","unstructured":"Shen, X. , Tang, H. , McDanal, C. , Wagh, K. , Fischer, W. , Theiler, J. , Yoon, H. , Li, D. , Haynes, B.F. , Sanders, K.O. , et al. (2021). SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. bioRxiv."},{"key":"2021030306150624000_2021.02.27.433180v1.48","unstructured":"Skelly, D.T. , Harding, A.C. , Gilbert-Jaramillo, J. , Knight, M.L. , Longet, S. , Brown, A. , Adele, S. , Adland, E. , Brown, H. , Medawar Laboratory Team., et al. (2020). Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern. Research square."},{"key":"2021030306150624000_2021.02.27.433180v1.49","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.14.1.1"},{"key":"2021030306150624000_2021.02.27.433180v1.50","doi-asserted-by":"crossref","unstructured":"Snyder, T.M. , Gittelman, R.M. , Klinger, M. , May, D.H. , Osborne, E.J. , Taniguchi, R. , Zahid, H.J. , Kaplan, I.M. , Dines, J.N. , Noakes, M.N. , et al. (2020). Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels. medRxiv.","DOI":"10.1101\/2020.07.31.20165647"},{"key":"2021030306150624000_2021.02.27.433180v1.51","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/pai.13263","article-title":"Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover","volume":"31","year":"2020","journal-title":"Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology"},{"key":"2021030306150624000_2021.02.27.433180v1.52","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3350"},{"key":"2021030306150624000_2021.02.27.433180v1.53","doi-asserted-by":"publisher","DOI":"10.1002\/cpmc.100"},{"key":"2021030306150624000_2021.02.27.433180v1.54","unstructured":"Stamatatos, L. , Czartoski, J. , Wan, Y.-H. , Homad, L.J. , Rubin, V. , Glantz, H. , Neradilek, M. , Seydoux, E. , Jennewein, M.F. , MacCamy, A.J. , et al. (2021). Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1. medRxiv, 2021.2002.2005.21251182."},{"key":"2021030306150624000_2021.02.27.433180v1.55","doi-asserted-by":"crossref","unstructured":"Starr, T.N. , Greaney, A.J. , Addetia, A. , Hannon, W.W. , Choudhary, M.C. , Dingens, A.S. , Li, J.Z. , and Bloom, J.D. (2021). Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science.","DOI":"10.1126\/science.abf9302"},{"key":"2021030306150624000_2021.02.27.433180v1.56","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","article-title":"Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding","volume":"182","year":"2020","journal-title":"Cell"},{"key":"2021030306150624000_2021.02.27.433180v1.57","unstructured":"Supasa, P. , Zhou, D. , Dejnirattisai, W. , Liu, C. , Mentzer, A.J. , Ginn, H.M. , Zhao, Y. , Duyvesteyn, H.M.E. , Nutalai, R. , Tuekprakhon, A. , et al. (2021). Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell."},{"key":"2021030306150624000_2021.02.27.433180v1.58","doi-asserted-by":"crossref","unstructured":"Tan, A.T. , Linster, M. , Tan, C.W. , Le Bert, N. , Chia, W.N. , Kunasegaran, K. , Zhuang, Y. , Tham, C.Y.L. , Chia, A. , Smith, G.J.D. , et al. (2021). Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell reports, 108728.","DOI":"10.1016\/j.celrep.2021.108728"},{"key":"2021030306150624000_2021.02.27.433180v1.59","doi-asserted-by":"crossref","first-page":"100204","DOI":"10.1016\/j.xcrm.2021.100204","article-title":"Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases","volume":"2","year":"2021","journal-title":"Cell reports Medicine"},{"key":"2021030306150624000_2021.02.27.433180v1.60","doi-asserted-by":"crossref","unstructured":"Tegally, H. , Wilkinson, E. , Giovanetti, M. , Iranzadeh, A. , Fonseca, V. , Giandhari, J. , Doolabh, D. , Pillay, S. , San, E.J. , Msomi, N. , et al. (2020). Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv, 2020.2012.2021.20248640.","DOI":"10.1101\/2020.12.21.20248640"},{"key":"2021030306150624000_2021.02.27.433180v1.61","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1006"},{"key":"2021030306150624000_2021.02.27.433180v1.62","doi-asserted-by":"crossref","unstructured":"Voloch, C.M. , Silva F, R.d. , de Almeida, L.G.P. , Cardoso, C.C. , Brustolini, O.J. , Gerber, A.L. , Guimar\u00e3es, A.P.d.C. , Mariani, D. , Costa, R.M.d. , Ferreira, O.C. , et al. (2020). Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. medRxiv, 2020.2012.2023.20248598.","DOI":"10.1101\/2020.12.23.20248598"},{"key":"2021030306150624000_2021.02.27.433180v1.63","unstructured":"Volz, E. , Mishra, S. , Chand, M. , Barrett, J.C. , Johnson, R. , Geidelberg, L. , Hinsley, W.R. , Laydon, D.J. , Dabrera, G. , O\u2019Toole, \u00c1. , et al. (2021). Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. medRxiv, 2020.2012.2030.20249034."},{"key":"2021030306150624000_2021.02.27.433180v1.64","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"2021030306150624000_2021.02.27.433180v1.65","doi-asserted-by":"crossref","unstructured":"Wang, P. , Liu, L. , Iketani, S. , Luo, Y. , Guo, Y. , Wang, M. , Yu, J. , Zhang, B. , Kwong, P.D. , Graham, B.S. , et al. (2021a). Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. bioRxiv, 2021.2001.2025.428137.","DOI":"10.1038\/s41586-021-03398-2"},{"key":"2021030306150624000_2021.02.27.433180v1.66","doi-asserted-by":"crossref","unstructured":"Wang, Z. , Schmidt, F. , Weisblum, Y. , Muecksch, F. , Barnes, C.O. , Finkin, S. , Schaefer-Babajew, D. , Cipolla, M. , Gaebler, C. , Lieberman, J.A. , et al. (2021b). mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. bioRxiv, 2021.2001.2015.426911.","DOI":"10.1038\/s41586-021-03324-6"},{"key":"2021030306150624000_2021.02.27.433180v1.67","unstructured":"Washington, N.L. , Gangavarapu, K. , Zeller, M. , Bolze, A. , Cirulli, E.T. , Barrett, K.M.S. , Larsen, B.B. , Anderson, C. , White, S. , Cassens, T. , et al. (2021). Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. medRxiv, 2021.2002.2006.21251159."},{"key":"2021030306150624000_2021.02.27.433180v1.68","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01108-14"},{"key":"2021030306150624000_2021.02.27.433180v1.69","unstructured":"Wibmer, C.K. , Ayres, F. , Hermanus, T. , Madzivhandila, M. , Kgagudi, P. , Lambson, B.E. , Vermeulen, M. , van den Berg, K. , Rossouw, T. , Boswell, M. , et al. (2021). SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv, 2021.2001.2018.427166."},{"key":"2021030306150624000_2021.02.27.433180v1.70","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2612"},{"key":"2021030306150624000_2021.02.27.433180v1.71","doi-asserted-by":"crossref","unstructured":"Wu, K. , Werner, A.P. , Koch, M. , Choi, A. , Narayanan, E. , Stewart-Jones, G.B.E. , Colpitts, T. , Bennett, H. , Boyoglu-Barnum, S. , Shi, W. , et al. (2021). Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine - Preliminary Report. N Engl J Med.","DOI":"10.1056\/NEJMc2102179"},{"key":"2021030306150624000_2021.02.27.433180v1.72","doi-asserted-by":"crossref","unstructured":"Zahradn\u00edk, J. , Marciano, S. , Shemesh, M. , Zoler, E. , Chiaravalli, J. , Meyer, B. , Dym, O. , Elad, N. , and Schreiber, G. (2021). SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor. bioRxiv, 2021.2001.2006.425392.","DOI":"10.1101\/2021.01.06.425392"},{"key":"2021030306150624000_2021.02.27.433180v1.73","doi-asserted-by":"crossref","unstructured":"Zhang, W. , Davis, B.D. , Chen, S.S. , Martinez, J.M.S. , Plummer, J.T. , and Vail, E. (2021). Emergence of a novel SARS-CoV-2 strain in Southern California, USA. medRxiv, 2021.2001.2018.21249786.","DOI":"10.1101\/2021.01.18.21249786"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2021.02.27.433180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:24:18Z","timestamp":1768440258000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.02.27.433180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":73,"URL":"https:\/\/doi.org\/10.1101\/2021.02.27.433180","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1016\/j.xcrm.2021.100355","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2021,3,1]]},"subtype":"preprint"}}